Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) EBT: 2020-2025

Historic EBT for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$11.0 million.

  • Insight Molecular Diagnostics' EBT rose 18.25% to -$11.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$61.3 million, marking a year-over-year decrease of 41.10%. This contributed to the annual value of -$61.0 million for FY2024, which is 142.84% down from last year.
  • Insight Molecular Diagnostics' EBT amounted to -$11.0 million in Q3 2025, which was down 12.25% from -$9.8 million recorded in Q2 2025.
  • In the past 5 years, Insight Molecular Diagnostics' EBT ranged from a high of $6.0 million in Q1 2023 and a low of -$35.8 million during Q4 2021.
  • Its 3-year average for EBT is -$10.3 million, with a median of -$9.1 million in 2024.
  • The largest annual percentage gain for Insight Molecular Diagnostics' EBT in the last 5 years was 157.90% (2023), contrasted with its biggest fall of 510.92% (2023).
  • Over the past 5 years, Insight Molecular Diagnostics' EBT (Quarterly) stood at -$35.8 million in 2021, then spiked by 66.42% to -$12.0 million in 2022, then plummeted by 34.63% to -$16.2 million in 2023, then crashed by 107.84% to -$33.6 million in 2024, then rose by 18.25% to -$11.0 million in 2025.
  • Its EBT stands at -$11.0 million for Q3 2025, versus -$9.8 million for Q2 2025 and -$6.8 million for Q1 2025.